Furthermore, we investigated Aurora-A inhibitors’ capacity to resensitize HCC cells to sorafenib via AKT/MAPK pathway modulation, establishing these inhibitors as promising therapeutic candidates against HCC’s aggressive biology (Zhang et al., 2018b). This evidence concerns the gene AKT1 and hepatocellular carcinoma.